Impact of pancreatic ductal occlusion on postoperative outcomes in pancreatic head cancer patients undergoing neoadjuvant therapy.
Malnutrition
Neoadjuvant therapy
Pancreatic ductal occlusion
Pancreatic exocrine insufficiency
Pancreatic head cancer
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
received:
22
02
2024
accepted:
04
06
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
20
6
2024
Statut:
aheadofprint
Résumé
Pancreatic ductal occlusion can accompany pancreatic head cancer, leading to pancreatic exocrine insufficiency (PEI) and adverse effects on nutritional status and postoperative outcomes. We investigated its impact on nutritional status, body composition, and postoperative outcomes in patients with pancreatic head cancer undergoing neoadjuvant therapy (NAT). We analyzed 136 patients with pancreatic head cancer who underwent NAT prior to intended pancreaticoduodenectomy (PD) between 2015 and 2022. Nutritional and anthropometric indices (body mass index [BMI], albumin, prognostic nutritional index [PNI], Glasgow prognostic score, psoas muscle index, subcutaneous adipose tissue index [SATI], and visceral adipose tissue index) and postoperative outcomes were compared between the occlusion (n = 78) and non-occlusion (n = 58) groups, in which 61 and 44 patients, respectively, ultimately underwent PD. The occlusion group showed significantly lower post-NAT BMI, PNI, and SATI (p = 0.011, 0.005, and 0.015, respectively) in the PD cohort. The occlusion group showed significantly larger main pancreatic duct, smaller pancreatic parenchyma, and greater duct-parenchymal ratio (p < 0.001), and these morphological parameters significantly correlating with post-NAT nutritional and anthropometric indices. Postoperative 3-year survival and recurrence-free survival (RFS) rates were significantly poorer (p = 0.004 and 0.013) with pancreatic ductal occlusion, also identified as an independent postoperative risk factor for overall survival (hazard ratio [HR]: 2.31, 95% confidence interval [CI] 1.08-4.94, p = 0.030) and RFS (HR: 2.03, 95% CI 1.10-3.72, p = 0.023), in multivariate analysis. Pancreatic ductal occlusion may be linked to poorer postoperative outcomes due to PEI-related malnutrition.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal occlusion can accompany pancreatic head cancer, leading to pancreatic exocrine insufficiency (PEI) and adverse effects on nutritional status and postoperative outcomes. We investigated its impact on nutritional status, body composition, and postoperative outcomes in patients with pancreatic head cancer undergoing neoadjuvant therapy (NAT).
METHODS
METHODS
We analyzed 136 patients with pancreatic head cancer who underwent NAT prior to intended pancreaticoduodenectomy (PD) between 2015 and 2022. Nutritional and anthropometric indices (body mass index [BMI], albumin, prognostic nutritional index [PNI], Glasgow prognostic score, psoas muscle index, subcutaneous adipose tissue index [SATI], and visceral adipose tissue index) and postoperative outcomes were compared between the occlusion (n = 78) and non-occlusion (n = 58) groups, in which 61 and 44 patients, respectively, ultimately underwent PD.
RESULTS
RESULTS
The occlusion group showed significantly lower post-NAT BMI, PNI, and SATI (p = 0.011, 0.005, and 0.015, respectively) in the PD cohort. The occlusion group showed significantly larger main pancreatic duct, smaller pancreatic parenchyma, and greater duct-parenchymal ratio (p < 0.001), and these morphological parameters significantly correlating with post-NAT nutritional and anthropometric indices. Postoperative 3-year survival and recurrence-free survival (RFS) rates were significantly poorer (p = 0.004 and 0.013) with pancreatic ductal occlusion, also identified as an independent postoperative risk factor for overall survival (hazard ratio [HR]: 2.31, 95% confidence interval [CI] 1.08-4.94, p = 0.030) and RFS (HR: 2.03, 95% CI 1.10-3.72, p = 0.023), in multivariate analysis.
CONCLUSIONS
CONCLUSIONS
Pancreatic ductal occlusion may be linked to poorer postoperative outcomes due to PEI-related malnutrition.
Identifiants
pubmed: 38900299
doi: 10.1007/s00535-024-02125-8
pii: 10.1007/s00535-024-02125-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
doi: 10.3322/caac.21763
pubmed: 36633525
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years After. Surgery. 2017;161:584–91.
doi: 10.1016/j.surg.2016.11.014
pubmed: 28040257
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142:761–8.
doi: 10.1016/j.surg.2007.05.005
pubmed: 17981197
Wente MN, Veit JA, Bassi C, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142:20–5.
doi: 10.1016/j.surg.2007.02.001
pubmed: 17629996
Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269:1154–62.
doi: 10.1097/SLA.0000000000002734
pubmed: 31082915
Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–44.
doi: 10.1007/s11605-009-0919-2
pubmed: 19418101
Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68–72.
doi: 10.1016/S0002-9610(05)80406-4
pubmed: 8380315
Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268–74.
doi: 10.1002/bjs.7305
pubmed: 20960457
Yamada S, Fujii T, Yabusaki N, et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer: glasgow prognostic score is the most reliable parameter. Medicine (Baltimore). 2016;95:e3582.
doi: 10.1097/MD.0000000000003582
pubmed: 27149487
Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;157:1088–98.
doi: 10.1016/j.surg.2015.02.002
pubmed: 25799468
Pecorelli N, Carrara G, De Cobelli F, et al. Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery. Br J Surg. 2016;103:434–42.
doi: 10.1002/bjs.10063
pubmed: 26780231
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38:1763–73.
doi: 10.1200/JCO.19.02274
pubmed: 32105518
pmcid: 8265386
Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter Phase 2/3 trial. Ann Surg. 2018;268:215–22.
doi: 10.1097/SLA.0000000000002705
pubmed: 29462005
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35:515–22.
doi: 10.1200/JCO.2016.68.5081
pubmed: 27621388
Sho M, Akahori T, Tanaka T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2013;20:197–205.
doi: 10.1007/s00534-012-0532-8
pubmed: 22766692
Tashiro M, Yamada S, Sonohara F, et al. Clinical impact of neoadjuvant therapy on nutritional status in pancreatic cancer. Ann Surg Oncol. 2018;25:3365–71.
doi: 10.1245/s10434-018-6699-8
pubmed: 30097739
Naumann P, Habermehl D, Welzel T, et al. Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer. Strahlenther Onkol. 2013;189:745–52.
doi: 10.1007/s00066-013-0393-3
pubmed: 23896631
Sandini M, Patino M, Ferrone CR, et al. Association between changes in body composition and neoadjuvant treatment for pancreatic cancer. JAMA Surg. 2018;153:809–15.
doi: 10.1001/jamasurg.2018.0979
pubmed: 29801062
pmcid: 6583880
Cooper AB, Slack R, Fogelman D, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol. 2015;22:2416–23.
doi: 10.1245/s10434-014-4285-2
pubmed: 25519927
Roeyen G, Berrevoet F, Borbath I, et al. Expert opinion on management of pancreatic exocrine insufficiency in pancreatic cancer. ESMO Open. 2022;7:100386.
doi: 10.1016/j.esmoop.2022.100386
pubmed: 35124465
pmcid: 8819032
Vujasinovic M, Valente R, Del Chiaro M, et al. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017;9:183.
doi: 10.3390/nu9030183
pubmed: 28241470
pmcid: 5372846
Toshima F, Watanabe R, Inoue D, et al. CT abnormalities of the pancreas associated with the subsequent diagnosis of clinical Stage I pancreatic ductal adenocarcinoma more than 1 year later: a case-control study. AJR Am J Roentgenol. 2021;217:1353–64.
doi: 10.2214/AJR.21.26014
pubmed: 34161128
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20:3794–801.
doi: 10.1245/s10434-013-3129-9
pubmed: 23838925
Okada KI, Hirono S, Kawai M, et al. Phase I study of nab-paclitaxel plus gemcitabine as neoadjuvant therapy for borderline resectable pancreatic cancer. Anticancer Res. 2017;37:853–8.
doi: 10.21873/anticanres.11389
pubmed: 28179342
Okada K, Kawai M, Hirono S, et al. Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial. Cancer Chemother Pharmacol. 2016;78:719–26.
doi: 10.1007/s00280-016-3121-8
pubmed: 27501851
Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.
doi: 10.1016/S0140-6736(16)30583-9
pubmed: 27265347
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335–9.
doi: 10.1001/archsurg.1992.01420110083017
pubmed: 1359851
Karasawa E, Goldberg HI, Moss AA, et al. CT pancreatogram in carcinoma of the pancreas and chronic pancreatitis. Radiology. 1983;148:489–93.
doi: 10.1148/radiology.148.2.6867347
pubmed: 6867347
Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.
doi: 10.1139/H08-075
pubmed: 18923576
DiMagno EP, Malagelada JR, Go VL. The relationships between pancreatic ductal obstruction and pancreatic secretion in man. Mayo Clin Proc. 1979;54:157–62.
pubmed: 431121
Tseng DS, Molenaar IQ, Besselink MG, et al. Pancreatic exocrine insufficiency in patients with pancreatic or periampullary cancer: a systematic review. Pancreas. 2016;45:325–30.
doi: 10.1097/MPA.0000000000000473
pubmed: 26495777
Sato N, Yamaguchi K, Chijiiwa K, et al. Duct-parenchymal ratio predicts exocrine pancreatic function after pancreatoduodenectomy and distal pancreatectomy. Am J Surg. 1998;176:270–3.
doi: 10.1016/S0002-9610(98)00144-5
pubmed: 9776157
Sugimoto M, Takahashi S, Kojima M, et al. In patients with a soft pancreas, a thick parenchyma, a small duct, and fatty infiltration are significant risks for pancreatic fistula after pancreaticoduodenectomy. J Gastrointest Surg. 2017;21:846–54.
doi: 10.1007/s11605-017-3356-7
pubmed: 28101719
Forsmark CE, Tang G, Xu H, et al. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Aliment Pharmacol Ther. 2020;51:958–67.
doi: 10.1111/apt.15698
pubmed: 32249970
pmcid: 7299155
Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42:92–6.
doi: 10.1136/gut.42.1.92
pubmed: 9505892
pmcid: 1726970
Seiler CM, Izbicki J, Varga-Szabó L, et al. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment Pharmacol Ther. 2013;37:691–702.
doi: 10.1111/apt.12236
pubmed: 23383603
pmcid: 3601428
Roberts KJ, Schrem H, Hodson J, et al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB (Oxford). 2017;19:859–67.
doi: 10.1016/j.hpb.2017.05.009
pubmed: 28711377
Seza K, Yamaguchi T, Ishihara T, et al. A long-term controlled trial of endoscopic pancreatic stenting for treatment of main pancreatic duct stricture in chronic pancreatitis. Hepatogastroenterology. 2011;58:2128–31.
pubmed: 22234084